New combo therapy shows promise for Hard-to-Treat GI cancers
NCT ID NCT05104567
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This study tested a new drug called SAR444245 (THOR-707) combined with other cancer treatments in 138 adults with advanced or metastatic gastrointestinal cancers, including esophageal, stomach, liver, and colorectal cancers. The goal was to see if the combination could shrink tumors in patients who had already tried other therapies. The trial is now complete, and results will help determine if this approach offers a meaningful benefit for these difficult-to-treat cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth Orlando Site Number : 8400005
Orlando, Florida, 32804, United States
-
City of Hope Site Number : 8400007
Duarte, California, 91010, United States
-
Investigational Site Number : 0560001
Leuven, 3000, Belgium
-
Investigational Site Number : 0560002
Brussels, BE-1200, Belgium
-
Investigational Site Number : 0560003
Edegem, 2650, Belgium
-
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, 8420383, Chile
-
Investigational Site Number : 1560002
Wuhan, 430022, China
-
Investigational Site Number : 2500001
Villejuif, 94800, France
-
Investigational Site Number : 2500002
Paris, 75015, France
-
Investigational Site Number : 2500004
Bordeaux, 33075, France
-
Investigational Site Number : 2500005
Poitiers, 86021, France
-
Investigational Site Number : 2500006
Brest, 29200, France
-
Investigational Site Number : 3800001
Rozzano, Lombardy, 20089, Italy
-
Investigational Site Number : 3800002
Milan, 20133, Italy
-
Investigational Site Number : 3800003
Milan, 20132, Italy
-
Investigational Site Number : 4100001
Seoul, Seoul-teukbyeolsi, 05505, South Korea
-
Investigational Site Number : 4100002
Seoul, Seoul-teukbyeolsi, 03080, South Korea
-
Investigational Site Number : 4100003
Seoul, Seoul-teukbyeolsi, 06351, South Korea
-
Investigational Site Number : 4100004
Seoul, Seoul-teukbyeolsi, 03722, South Korea
-
Investigational Site Number : 5280001
Amsterdam, 1081 HV, Netherlands
-
Investigational Site Number : 5280003
Rotterdam, 3015 GD, Netherlands
-
Investigational Site Number : 7240001
Pamplona, Navarre, 31008, Spain
-
Investigational Site Number : 7240002
Barcelona, Barcelona [Barcelona], 08035, Spain
-
Investigational Site Number : 7240003
Madrid / Madrid, Madrid, Comunidad de, 28007, Spain
-
Investigational Site Number : 7240004
Madrid / Madrid, Madrid, Comunidad de, 28050, Spain
-
Investigational Site Number : 7240005
Santander, Cantabria, 39008, Spain
-
Investigational Site Number : 7240006
Barcelona, Barcelona [Barcelona], 08036, Spain
-
Investigational Site Number : 7240101
Madrid, Madrid, Comunidad de, 28027, Spain
-
Seattle Cancer Care Alliance Site Number : 8400009
Seattle, Washington, 98115, United States
Conditions
Explore the condition pages connected to this study.